Pharmacological interventions for improving adenovirus usage in gene therapy

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Cancer Research

Background:

• Gene therapy offers potential for cancer treatment but is hindered by low delivery efficiency and specificity.
• Adenovirus vectors are favored for systemic gene delivery due to high in vivo transduction rates.
• Adenovirus administration faces challenges with liver sequestration by Kupffer cells, hepatocytes, and endothelial cells.

Purpose of the Study:

• To investigate the mechanisms of adenovirus sequestration in the liver following intravenous administration.
• To explore strategies for overcoming liver cell binding to improve systemic adenovirus gene therapy efficacy.
• To enhance the potential for successful systemic application of adenovirus-based cancer gene therapy in humans.

Main Methods:

• Analysis of adenovirus binding to Kupffer cells, hepatocytes, and sinusoid endothelial cells at varying doses.
• Evaluation of RGD motif-dependent binding to sinusoid endothelial cells.
• Review of strategies including drug interference, capsid protein mutations, and chemical modifications to prevent liver cell binding.

Main Results:

• Adenovirus initially binds to Kupffer cells via scavenger receptors.
• Hepatocyte and sinusoid endothelial cell uptake occurs at higher doses, with specific binding mechanisms identified.
• Several strategies, including drug interference and adenovirus modifications, are proposed to mitigate liver sequestration.

Conclusions:

• Understanding adenovirus-liver cell interactions is crucial for optimizing systemic gene therapy.
• Targeted strategies can potentially overcome liver sequestration, improving adenovirus vector efficiency.
• Combined approaches hold promise for the successful clinical application of adenovirus gene therapy.